Sorrento Therapeutics Shanghai Co., Ltd. Sustainability Profile
Sorrento Therapeutics Shanghai Co., Ltd., a subsidiary of Sorrento Therapeutics, Inc., is a prominent player in the biopharmaceutical industry, headquartered in the United States. Established in 2006, the company has made significant strides in the development of innovative therapies, particularly in oncology and immunology. With major operations in Shanghai, Sorrento Therapeutics focuses on advancing its proprietary antibody and cell therapy platforms, which are designed to address unmet medical needs. The company is renowned for its unique approach to drug development, leveraging cutting-edge technologies to create targeted therapies. Sorrento Therapeutics has achieved notable milestones, including successful clinical trials and strategic partnerships that enhance its market position. As a leader in the biopharmaceutical sector, Sorrento Therapeutics continues to push the boundaries of science, aiming to deliver transformative treatments to patients worldwide.
DitchCarbon Score
How does Sorrento Therapeutics Shanghai Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sorrento Therapeutics Shanghai Co., Ltd.'s score of 5 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sorrento Therapeutics Shanghai Co., Ltd.'s reported carbon emissions
Sorrento Therapeutics Shanghai Co., Ltd., a subsidiary of Sorrento Therapeutics, Inc., currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. Consequently, there are no recorded emissions in kg CO2e for the most recent year or any previous years. As a current subsidiary, Sorrento Therapeutics Shanghai may inherit climate commitments and initiatives from its parent company, Sorrento Therapeutics, Inc. However, no specific reduction targets or climate pledges have been identified for Sorrento Therapeutics Shanghai. The company does not appear to have set Science-Based Targets Initiative (SBTi) reduction targets or any documented climate initiatives. In the context of the industry, it is essential for companies like Sorrento Therapeutics Shanghai to establish clear climate commitments and emissions reduction strategies to align with global sustainability goals. The lack of reported emissions data and reduction initiatives highlights an opportunity for the company to enhance its environmental accountability and contribute to broader climate action efforts.
How Carbon Intensive is Sorrento Therapeutics Shanghai Co., Ltd.'s Industry?
How Carbon Intensive is Sorrento Therapeutics Shanghai Co., Ltd.'s Location?
Sorrento Therapeutics Shanghai Co., Ltd.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Sorrento Therapeutics Shanghai Co., Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
